Stroke Update 2009: 뇌졸중의 위험인자 및 일차 예방
Stroke Update 2009: Recent Advances on Stroke Risk Factors & Primary Prevention
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Stroke is a heterogeneous, multifactorial disease regulated by various modifiable and nonmodifiable risk factors. Theoretically almost 80% of stroke events could be reduced by making simple lifestyle modifications. In 2008, a lot of studies potentially in-fluencing the primary prevention of stroke had been reported. This review discusses recently completed studies that have the potential to impact clinical practice. The topics discussed include hypertension, diabetes mellitus, dyslipidemia and statin therapy. (Korean J Stroke 2009;11:62-66)
Abstract
Stroke is a heterogeneous, multifactorial disease regulated by various modifiable and nonmodifiable risk factors. Theoretically almost 80% of stroke events could be reduced by making simple lifestyle modifications. In 2008, a lot of studies potentially in-fluencing the primary prevention of stroke had been reported. This review discusses recently completed studies that have the potential to impact clinical practice. The topics discussed include hypertension, diabetes mellitus, dyslipidemia and statin therapy. (Korean J Stroke 2009;11:62-66)
참고문헌 (16)
- Beckett NS, "Treatment of Hypertension in Patients 80 Years of Age or Older", N Engl J Med, 358, pp.1887~1898 (2008)
- Yusuf S, "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators", N Engl J Med, 342, pp.145~153 (2000)
- The ONTARGET Investigators, "Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events", N Engl J Med, 358, pp.1547~1559 (2008)
- Yusuf S, "Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial", Lancet, 372, pp.1174~1183 (2008)
- Jamerson K, "Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients", N Engl J Med, 359, pp.2417~2428 (2008)
- "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group", Lancet, 352, pp.837~853 (1998)
- "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group", BMJ, 317, pp.703~713 (1998)
- Holman RR, "10-year follow-up of intensive glucose control in type 2 diabetes", N Engl J Med, 359, pp.1577~1589 (2008)
- Holman RR, "Longterm follow-up after tight control of blood pressure in type 2 diabetes", N Engl J Med, 359, pp.1565~1576 (2008)
- Patel A, "Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes", N Engl J Med, 358, pp.2560~2572 (2008)
- Gerstein HC, "Effects of intensive glucose lowering in type 2 diabetes", N Engl J Med, 358, pp.2545~2559 (2008)
- Duckworth W, "Glucose control and vascular complications in veterans with type 2 diabetes", N Engl J Med, 360, pp.129~139 (2009)
- Skyler JS, "American Diabetes Association; American College of Cardiology Foundation; American Heart Association. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association", Circulation, 119, pp.351~357 (2009)
- Ridker PM, "Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein", N Engl J Med, 359, pp.2195~2207 (2008)
- Freiberg JJ, "Nonfasting triglycerides and risk of ischemic stroke in the general population", JAMA, 300, pp.2142~2152 (2008)
- Ogawa H, "Trial Investigators. Lowdose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial", JAMA, 300, pp.2134~2141 (2008)